Conservation of in vitro drug resistance patterns in epithelial ovarian carcinoma

Gynecologic Oncology

Volumn 98, Issue 3, 2005, Pages 360-368

  Tewari, Krishnansu S ^a   Mehta, Rita S ^a,b   Burger, Robert A ^a   Yu, Ing Ru ^b   Kyshtoobayeva, Ainura S ^b   Monk, Bradley J ^a   Manetta, Alberto ^a   Berman, Michael L ^a   Disaia, Philip J ^a   Fruehauf, John P ^a,b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Oncotech Inc   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Acquired resistance; Chemoresistance assay; Tumor heterogeneity

Indexed keywords

4 HYDROXYCYCLOPHOSPHAMIDE; CISPLATIN; PACLITAXEL; THYMIDINE; TOPOTECAN;

ARTICLE; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER STAGING; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IN VITRO STUDY; OVARY CARCINOMA; OVARY METASTASIS; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE;

CISPLATIN; CYCLOPHOSPHAMIDE; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; NEOPLASM METASTASIS; NEOPLASMS, MULTIPLE PRIMARY; NEOPLASMS, SECOND PRIMARY; OVARIAN NEOPLASMS; PACLITAXEL; TOPOTECAN;

EID: 23844494391     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ygyno.2005.04.036     Document Type: Article

References (30)

1. P.J. DiSaia, and K.S. Tewari Recent advancements in the treatment of epithelial ovarian cancer J. Obstet. Gynaecol. Res. 27 2001 61 75
2. A. Jemal, T. Murray, E. Ward, A. Samuels, R.C. Tiwari, A. Ghafoor, E.J. Feuer, and M.J. Thun Cancer statistics, 2005 CA Cancer J. Clin. 55 1 2005 10 30
3. W.P. McGuire, W.J. Hoskins, and M.F. Brady Cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer N. Eng. J. Med. 334 1996 1 6
4. D.S. Alberts Treatment of refractory and recurrent ovarian cancer Semin. Oncol. 26 1999 S8 S14
5. M. Markman, and M.A. Bookman Second-line treatment of ovarian cancer Oncologist 5 2000 26 35
6. E. Chu, and V. DeVita Principles of cancer management: chemotherapy V. DeVita S. Hellman S. Rosenberg Cancer: principles and practice of oncology 2001 Lippincott Williams and Wilkins
7. J.P. Fruehauf, and A.G. Bosanquet In vitro determinations of drug response: a discussion of clinical applications Princ. Pract. Oncol., Upd. 7 1993 1 16
8. P. Cortazar, and B.E. Johnson Review of the efficacy of individualized chemotherapy selected by in vitro drug sensitivity testing for patients with cancer J. Clin. Oncol. 17 1999 1625 1631
9. D.H. Kern, and L.M. Weisenthal Highly specific prediction of antineoplastic drug resistance with an in vitro assay using suprapharmacologic drug doses J. Natl. Cancer Inst. 82 1990 582 588
10. R.S. Mehta, R. Bornstein, and I.R. Yu Breast cancer survival and in vitro tumor response in the extreme drug resistance assay Breast Cancer Res. Treat. 66 2001 225 237
11. R.W. Holloway, R.S. Mehta, and N. Finkler Association between in vitro platinum resistance in the EDR assay and clinical outcomes for ovarian cancer patients Gynecol. Oncol. 87 2002 8 16
12. J.P. Fruehauf, and A. Manetta Use of the extreme drug resistance assay to evaluate mechanisms of resistance in ovarian cancer: taxol resistance and MDR-1 expression Contrib. Gynecol. Obstet. 19 1994 39 52
13. R. Larsson, and P. Nygren Prediction of individual patient response to chemotherapy by the fluorometric microculture cytotxicity assay (FMCA) using drug specific cut-off limits and a Bayesian model Anticancer Res. 13 5C 1993 1825 1829
14. J.R. Landis, and G.G. Koch An application of hierarchical kappa-type statistics in the assessment of majority agreement among multiple observers Biometrics 33 1977 363 374
15. I.J. Jacobs, M.F. Kohler, and R.W. Wiseman Clonal origin of epithelial ovarian carcinoma: analysis by loss of heterozygosity, p53 mutation, and X-chromosome inactivation J. Natl. Cancer Inst. 84 1992 1793 1798
16. B-U. Sevin, and J.P. Perras Tumor heterogeneity and in vitro chemosensitivity testing in ovarian cancer Am. J. Obstet. Gynecol. 176 1997 759 768
17. J.H. Goldie, and A.J. Coldman A mathematical model for relating the drug sensitivity of tumors to their spontaneous mutation rate Cancer Treat. Rep. 63 1979 1727 1733
18. C.G. Taylor, J.M. Sargent, and A.W. Elgie The clinical relevance of chemosensitivity testing in ovarian cancer Cancer Detect. Prev. 22 1998 305 312
19. K. Tewari, and A. Manetta In vitro chemosensitivity testing and mechanisms of drug resistance Current Oncol. Rep. 1 1999 77 84
20. B-U. Sevin, J.P. Perras, and H.E. Averette Chemosensitivity testing in ovarian cancer Cancer 71 1993 1613 1620
21. K.S. Tewari, A.S. Kyshtoobayeva, and R.S. Mehta Biomarker conservation in primary and metastatic epithelial ovarian carcinoma Gynecol. Oncol. 78 2000 130 136
22. J.M. Xu, S.T. Song, and Z.M. Tang Predictive chemotherapy of advanced breast cancer directed by MTT assay in vitro Breast Cancer Res. Treat. 53 1999 77 85
23. C.M. Kurbacher, I.A. Cree, and H.W. Bruckner Use of an ex vivo ATP luminescence assay to direct chemotherapy for recurrent ovarian cancer Anticancer Drugs 9 1998 51 57
24. K. Fujita, T. Kubota, and S.W. Matsuzaki Further evidence for the value of the chemosensitivity test in deciding appropriate chemotherapy for advanced gastric cancer Anticancer Res. 18 1998 1973 1978
25. B.E. Hillner Medical decision making: a Bayesian approach to laboratory testing Med. Sect. Proc. 1987 27 37
26. J.W. Orr Jr., P. Orr, and D.H. Kern Cost-effective treatment of women with advanced ovarian cancer by cytoreductive surgery and chemotherapy directed by an in vitro assay for drug resistance Cancer J. Sci. Am. 5 1999 174 178
27. D. Schrag, H.S. Garewal, and H.J. Burstein American Society of Clinical Oncology Technology Assessment: chemotherapy sensitivity and resistance assays J. Clin. Oncol. 22 2004 3631 3638
28. R.F. Ozols Gynecologic Oncology Group trials in ovarian carcinoma Semin. Oncol. 24 1997 S2-10 S2-12
29. R.E. Hempling, J.A. Wesolowski, and M.S. Piver Second-look laparotomy in advanced ovarian cancer: a critical assessment of morbidity and impact on survival Ann. Surg. Oncol. 4 1997 349 354
30. L. Williams, V.L. Brunetto, and E. Yordan Secondary cytoreductive surgery at second-look laparotomy in advanced ovarian cancer: a Gynecologic Oncology Group Study Gynecol. Oncol. 66 1997 171 178